drugset / Trial / NCT04511078
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.
Timeline
- Start
- 2021-04-02
- Primary completion
- 2030-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 50 mg | — |